Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Retatrutide's novel triple-agonist approach produced 28.7% weight loss in Phase 3 TRIUMPH-4 (confirming 24.2% in Phase 2) by adding glucagon and GIP receptor activation
Patients are supported every step of the way, ensuring safety and sustainable results
Dhaliwal JS, Spurling BC, Molla M
the main reported adverse events were mild to moderate, and included diarrhea, constipation and loss of appetite
US$ 28.98
US$ 27.80
US$ 21.15
US$ 25.74
US$ 29.22
US$ 22.24
